Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY | Market Cap | 9.19T +30.3% |
| Revenue (ttm) | 4.62T +3.1% |
| Net Income | -163.44B |
| EPS | -103.52 |
| Shares Out | 1.60B |
| PE Ratio | n/a |
| Forward PE | 40.36 |
| Dividend | 204.00 (3.45%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 5,384,700 |
| Open | 5,757.00 |
| Previous Close | 5,908.00 |
| Day's Range | 5,647.00 - 5,759.00 |
| 52-Week Range | 4,102.00 - 6,033.00 |
| Beta | 0.10 |
| Analysts | Buy |
| Price Target | 6,559.56 (+14.02%) |
| Earnings Date | Oct 29, 2026 |
About TYO:4502
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enan... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for 4502 stock is "Buy." The 12-month stock price target is ¥6,560, which is an increase of 14.02% from the latest price.
News
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 ...
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals buil...
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously delivered first-in-class hepcidin mimetic peptide fo...
FDA Approves Takeda's Mimrylo For Rare Blood Disorder Polycythemia Vera
(RTTNews) - The U.S. Food and Drug Administration approved Takeda Pharmaceutical's (TAK, TKPHF, 4502.T) Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder t...
Takeda receives FDA approval of NDA for Mimrylo
Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for...
US FDA approves Takeda, Protagonist's drug for rare blood cancer
The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, the health regulator said o...
Takeda announces Japan MHLW approval for Orzeyful
Takeda (TAK) announced that the Japanese Ministry of Health, Labour and Welfare, or MHLW, approved the use of Orzeyful for the treatment of narcolepsy type 1 in adults. Orzeyful is…
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for ...
A Look at Takeda Pharmaceutical Co Ltd (TAK) After 3.9% Gain -- GF Value $14.36 vs Price $18.05
A Look at Takeda Pharmaceutical Co Ltd (TAK) After 3.9% Gain -- GF Value $14.36 vs Price $18.05
Tuesday's ETF Movers: PPH, PTF
In trading on Tuesday, the VanEck Pharmaceutical ETF is outperforming other ETFs, up about 2% on the day. Components of that ETF showing particular strength include shares of Bausch Health Companies, ...
Wall Street Analysts Think Takeda Pharmaceutical Co. (TAK) Could Surge 26.41%: Read This Before Placing a Bet
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...
Takeda award from Veterans Affairs posted to SAM.gov site
A contract award dated August 7 from Department of Veterans Affairs to Takeda (TAK) Pharmaceuticals America was posted to the SAM.gov website. The total contract value for the base and…
FDA approves Takeda’s Orzeyful to treat narcolepsy type 1
Takeda (TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL, an oral orexin receptor 2 agonist, for the treatment of narcolepsy type 1 in adults. The persistent…
U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2...
US FDA approves Takeda's sleep disorder pill
The FDA has approved Takeda Pharmaceuticals' oral drug for narcolepsy, the U.S. health regulator said on Wednesday, backing the first treatment that targets all the symptoms of the rare sleep disord...
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
Keros Therapeutics (KROS) announced that it will receive a $20M development milestone payment under the terms of the license agreement of elritercept with partner Takeda (TAK), following the dosing of...
Takeda Pharmaceutical Q1 Earnings Call Highlights
Takeda Pharmaceutical NYSE: TAK said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its...
Takeda Pharmaceutical Company Earnings Call Transcript: Q1 2027
Q1 FY2026 results were in line with expectations, with core revenue and profit slightly down at CER but strong FX gains. Launch preparations for ORZEYFUL, rusfertide, and zasocitinib are progressing, and full-year guidance is reaffirmed.
Takeda Pharmaceutical Company Quarterly report: Q1 2027
Takeda Pharmaceutical Company has published its Q1 2027 quarterly earnings report on July 30, 2026.
Takeda Pharmaceutical Company Slides: Q1 2027
Takeda Pharmaceutical Company has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined exec...
Takeda dengue vaccine receives marketing authorization from India DCGI
Takeda (TAK) announced that India’s Drug Controller General of India, or DCGI, has granted marketing authorization for Takeda’s dengue vaccine for the prevention of dengue disease in individuals four ...